---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: STRIDE open-label extension"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: STRIDE open-label extension. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 57 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/stride-open-label-extension"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: STRIDE open-label extension

<a id="heading-3.1.5"></a>

## 3.1.5 STRIDE Open-label Extension

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Objective of the 52-week analysis

> “To assess long-term safety and efficacy of envudeucitinib throughout 52 weeks in the ongoing phase 2 open-label extension in patients who completed STRIDE.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.1-2"></a>

#### Purpose of the open-label extension in the ClinicalTrials.gov record

> “This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.”
> “A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Study start, completion, and record dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-01-17”
> “Primary Completion (Estimated) 2027-12-01”
> “Study Completion (Estimated) 2027-12-31”
> “First Posted 2023-02-22”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.2-2"></a>

#### Completion dates estimated at registration, February 2023, superseded in July 2026

> “Primary Completion 2026-12-01 [Estimated]”
> “Study Completion 2026-12-30 [Estimated]”

Source: [ClinicalTrials.gov NCT05739435 version 1](https://clinicaltrials.gov/study/NCT05739435?tab=history&a=1)

<a id="topic-3.1.5.2-3"></a>

#### Recruitment status and last update in the ClinicalTrials.gov record

> “Last Update Posted 2026-07-28 Active, not recruiting No longer looking for participants”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.2-4"></a>

#### Countries of trial sites in the ClinicalTrials.gov record

> “This study has 38 locations”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

| Country | A site listed for the country in the record |
| --- | --- |
| United States | “Rogers, Arkansas, United States, 72758” |
| Canada | “Surrey, British Columbia, Canada, V3V 0C6” |

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.2-5"></a>

#### North American sites and date of first entry into the open-label extension

> “This study was conducted at North American sites only.”
> “Of note, the first patient entered OLE on 17 January 2023.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Design in the ClinicalTrials.gov record

> “Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : None (Open Label)”
> “Patients have the option to remain on study until ESK-001 is commercially available.”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.3-2"></a>

#### Ongoing phase 2 extension with enrollment within 28 days of the STRIDE end-of-study visit

> “The OLE is an ongoing phase 2 study (NCT05739435) to assess the safety and efficacy of envudeucitinib in adults with moderate-to-severe plaque psoriasis who completed STRIDE.”
> “Patients were eligible for the OLE regardless of treatment response in STRIDE and were enrolled at the time of or within 28 days following the STRIDE end-of-study visit.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.3-3"></a>

#### Protocol amendment of January 2024 moving all participants to 40 mg twice daily

> “During the study, data from STRIDE3 and interim OLE data indicated that the 40-mg BID dose offered the most robust benefit/risk profile compared to the QD regimen. The findings prompted a protocol amendment on 2 January 2024 to transition all patients in the study to the 40-mg BID dose (between weeks 40 and 64).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.3-4"></a>

#### Visit and pharmacokinetic sampling schedule

> “Patients were assessed for safety and efficacy at study visit day 1, weeks 2, 4, 8, 12, 16, and every 12 weeks thereafter. Pharmacokinetic (PK) samples were collected throughout the 52 weeks on day 1, weeks 4, 16, and every 6 months thereafter.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.3-5"></a>

#### Rollover after the STRIDE week 16 visit and timing of the switch to twice-daily dosing

> “Eligible patients rolled over to the OLE study following completion of the STRIDE end-of-study visit at Week 16. Upon clear identification of the most beneficial dose, 40-mg QD patients switched to the 40-mg BID arm between Weeks 40 and 64.”

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Inclusion and exclusion criteria in the ClinicalTrials.gov record

> “Must have completed a prior ESK-001 study”
> “Men and Women must use highly effective methods of contraception for the entirety of the study”
> “Exclusion Criteria: Pregnancy Received a prohibited concomitant medication”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.4-2"></a>

#### Eligibility criteria and prohibited treatments in the supplementary material

> “Eligible patients were adult males or nonpregnant females who completed the envudeucitinib Phase 2 STRIDE study and consented to participate in the OLE study.”
> “Patients were excluded from the study if, after the last dose of envudeucitinib in the STRIDE study and prior to entering the OLE, they developed a new acute or chronic illness/condition or evidence of an unstable existing clinical condition that could have increased their safety risk, or if they received a prohibited concomitant medication.”
> “Prohibited treatments were those medications used for treatment of plaque psoriasis, including but not limited to systemic corticosteroids; topical medications that could affect psoriasis evaluation; phototherapy; therapeutic agents targeting IL12/23, IL-23, or IL-17; TYK2 inhibitors; or any investigational agents.”

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Allocation to 40 mg once or twice daily by STRIDE dose arm

> “At the time of enrollment, patients were assigned to 40-mg QD or 40-mg BID”
> “Patients receiving 10-mg QD or 20-mg QD in STRIDE entered the 40-mg QD OLE arm, while those on 20-mg or 40-mg BID in STRIDE entered the 40-mg BID OLE arm; STRIDE patients on placebo and 40-mg QD were allocated to either OLE dose arm”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.5-2"></a>

#### Numbers allocated to each extension arm from each STRIDE arm

> “All OLE patients enrolled from the STRIDE 10 mg QD (n=30) and 20 mg QD (n=26) arms entered the 40-mg QD OLE arm; all OLE enrolled patients from the STRIDE 20 mg BID (n=29) and 40mg BID (n=27) arms entered the OLE 40-mg BID arm.”
> “Patients from the STRIDE placebo and 40-mg QD arms were allocated as follows: OLE 40-mg QD arm included 9 and 17 patients from STRIDE 40-mg QD and placebo arms, respectively; OLE 40 mg BID included 17 and 9 patients from STRIDE 40-mg QD and placebo arms, respectively”

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="topic-3.1.5.5-3"></a>

#### Arms and interventions in the ClinicalTrials.gov record

> “Experimental: envudeucitinib Dose Level 1 envudeucitinib administered as an oral tablet”
> “Experimental: envudeucitinib Dose Level 2 envudeucitinib administered as an oral tablet”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Treatment-emergent and Serious Adverse Events as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Primary and secondary endpoints in the publication

> “The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). The secondary endpoints were as follows: change from baseline in Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA), body surface area (%BSA), and pruritus Numerical Rating Scale (NRS) to assess long-term efficacy; change from baseline in Dermatology Life Quality Index (DLQI) to assess the change in quality of life (QoL); and envudeucitinib plasma concentrations and PK parameters. Safety assessments also included vital signs, clinical laboratory assessments, and electrocardiograms (ECGs).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.6.1-2"></a>

##### Primary and secondary outcomes in the ClinicalTrials.gov record

| Outcome | Outcome measure | Measure description and time frame |
| --- | --- | --- |
| Primary | “To assess the safety and tolerability of long-term ESK-001 treatment” | “Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) Approximately 3 years” |
| Secondary | “To assess the long-term efficacy of ESK-001” | “Change from baseline in Psoriasis Area and Severity Index (PASI) over time Approximately 3 years” |
| Secondary | “To assess the change in quality of life (QoL) with long-term ESK-001 administration” | “Change from baseline in Dermatology Life Quality Index (DLQI) over time Approximately 3 years” |
| Secondary | “To assess the pharmacokinetics (PK) of ESK-001 (ctrough)” | “Plasma concentrations and PK parameters including steady-state trough observed plasma concentration (Ctrough) for ESK-001 2 years” |

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.6.1-3"></a>

##### Regulatory guidance on one-year exposure in the safety database

> “Therefore, some patients should be treated with the drug for 12 months.”
> “100 patients exposed for a minimum of one-year is considered to be acceptable to include as part of the safety data base.”

Source: [ICH E1 population exposure guideline (1995)](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-1-population-exposure-extent-population-exposure-assess-clinical-safety-step-5_en.pdf)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 165”

Source: [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435)

<a id="topic-3.1.5.7.1-2"></a>

##### Enrollment estimated at registration, February 2023, superseded in May 2024

> “Masking None (Open Label) Allocation Randomized Enrollment 210 [Estimated]”

Source: [ClinicalTrials.gov NCT05739435 version 1](https://clinicaltrials.gov/study/NCT05739435?tab=history&a=1)

<a id="topic-3.1.5.7.1-3"></a>

##### Sample size based on STRIDE completers without a power calculation

> “Formal power calculations were not performed to determine the sample size. The number of patients included in this study was based on the number of patients who completed STRIDE, qualified for, and chose to enroll in this study.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Modified intent-to-treat, safety, and pharmacokinetic populations and modified non-responder imputation

> “All efficacy analyses were based on the modified intent-to-treat (mITT) analysis population, which included all patients who received at least 1 dose of study drug according to the assigned treatment. For efficacy analyses, baseline was defined as the patients' values obtained on Day 1 of STRIDE. A modified non-responder imputation (mNRI) was applied for responder-type analyses where patients who discontinued the study due to adverse events (AEs) or inadequate response were treated as non-responders and patients who discontinued for all other reasons had their last observation carried forward. The safety analysis population included all patients who received at least 1 dose of study drug analyzed according to the actual treatment received. The PK analysis population included patients who received at least 1 dose of envudeucitinib and had at least one PK concentration measurement.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.7.2-2"></a>

##### Composition of the 40 mg once-daily and overall 40 mg twice-daily groups in the safety and efficacy tables

> “Envudeucitinib 40-mg QD data presented is for all patients who were dosed with 40-mg QD up to the time of discontinuation from envudeucitinib treatment or switch to 40-mg BID. Envudeucitinib 40-mg BID data presented is for all patients reaching week 52, including patients who were randomized to envudeucitinib 40-mg BID from the start of OLE and who switched from 40-mg QD to 40-mg BID.”
> “The week 28 data is presented for original envudeucitinib 40-mg QD. These patients then switched to 40-mg BID after week 28. The week 52 data is presented for the original and overall envudeucitinib 40-mg BID cohorts. Overall envudeucitinib 40-mg BID includes those who switched from 40-mg QD to 40-mg BID, and patients who were originally assigned to envudeucitinib 40-mg BID.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.7.2-3"></a>

##### Analysis sets by arm, ITT population

| Analysis set | Original 40 mg QD (N = 82) | Original 40 mg BID (N = 83) | 40 mg QD to 40 mg BID (N = 65) | Overall 40 mg BID (N = 148) | Overall (N = 165) |
| --- | --- | --- | --- | --- | --- |
| ITT population | “82” | “83” | “65” | “148” | “165” |
| mITT population | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |
| Safety analysis set | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |
| PK analysis set | “82 (100.0)” | “82 (98.8)” | “65 (100.0)” | “147 (99.3)” | “164 (99.4)” |

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="topic-3.1.5.7.2-4"></a>

##### Post-hoc treat-to-target analyses and mixed model for percent change in PASI

> “Achievement of treat-to-target thresholds at Week 12 of STRIDE and Week 52 of OLE was performed as a post-hoc analysis. All p-values presented are nominal.”
> “LS Means and 95% confidence interval (CI) of percent change from baseline of PASI total score was based on a mixed model repeated measures (MMRM) analysis.”

Source: [Armstrong et al. (2025c)](https://www.alumis.com/file.cfm/613/docs/2025_fall_clinical_dermatology_conference.pdf)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Rollover from STRIDE: randomized, completing, ineligible, and declining participants

> “95% of Eligible STRIDE Subjects Continued in OLE Study”
> “228 Randomized Phase 2 STRIDE Subjects”
> “204 Subjects Completing STRIDE”
> “30 Ineligible and not participating in OLE”
> “25: OLE Not initiated in Czech Republic”
> “5: Did not meet OLE inclusion criteria”
> “9 Eligible for OLE but chose not to participate”

Source: [Blauvelt et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv_late_breaker_presentation_final.pdf)

<a id="topic-3.1.5.8.1-2"></a>

##### Enrollment of 165 participants and one participant not dosed

> “A total of 165 patients were enrolled in this OLE study. One enrolled patient was diagnosed with coronary artery occlusion at week 16 of STRIDE3 (at day 1 of the OLE) prior to dosing in OLE and, therefore, came off study.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.1-3"></a>

##### Participants ongoing and discontinuations at the 52-week data cut-off

> “Treatment was ongoing for 126 patients (76.4%) of the 165 patients enrolled in the OLE at the cut-off date for the 52-week data analyses”
> “Overall, most study discontinuations were due to withdrawal by patient (7.9%) or lost to follow-up (6.1%)”
> “One patient discontinued from study due to pregnancy and 1 due to partner's pregnancy. Six patients (3.7%) discontinued envudeucitinib due to an AE (Table II). Out of these patients, 1 discontinued envudeucitinib due to an AE of osteomyelitis, but had not discontinued the study at the time of the cut-off date.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.1-4"></a>

##### Disposition by arm, ITT population

| Disposition | Original 40 mg QD (N = 82) | Original 40 mg BID (N = 83) | 40 mg QD to 40 mg BID (N = 65) | Overall 40 mg BID (N = 148) | Overall (N = 165) |
| --- | --- | --- | --- | --- | --- |
| Patients ongoing in study, n (%) | “0 (0)” | “66 (79.5)” | “60 (92.3)” | “126 (85.1)” | “126 (76.4)” |
| Patients who switched to 40 mg BID, n (%) | “65 (79.3)” | “-” | “-” | “-” | “65 (39.4)” |
| Discontinued: withdrawal by subject | “6 (7.3)” | “3 (3.6)” | “4 (6.2)” | “7 (4.7)” | “13 (7.9)” |
| Discontinued: lost to follow-up | “3 (3.7)” | “6 (7.2)” | “1 (1.5)” | “7 (4.7)” | “10 (6.1)” |
| Discontinued: inadequate response | “6 (7.3)” | “1 (1.2)” | “0 (0)” | “1 (0.7)” | “7 (4.2)” |
| Discontinued: adverse event | “1 (1.2)” | “4 (4.8)” | “0 (0)” | “4 (2.7)” | “5 (3.0)” |
| Discontinued: pregnancy | “1 (1.2)” | “0 (0)” | “0 (0)” | “0 (0)” | “1 (0.6)” |
| Discontinued: protocol deviation | “0 (0)” | “1 (1.2)” | “0 (0)” | “1 (0.7)” | “1 (0.6)” |
| Discontinued: death | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” | “0 (0)” |

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="topic-3.1.5.8.1-5"></a>

##### Basis of the disposition counts, data date, and the participant not dosed

> “The numbers and percentages of patients discontinued from the study are summarized based on the treatment that the patients were receiving at the time of discontinuation. The numbers and percentages of patients ongoing in the study are summarized based on the treatment that the patients were receiving at the time of data cut.”
> “Data from 18 November 2024 is included.”
> “Patient did not receive dose due to incidental finding of coronary artery occlusion on the last day of STRIDE Phase 2 (Week 16)/Day 1 of OLE. The patient was successfully treated by stent placement procedure. The patient received envudeucitinib 20 mg BID during STRIDE and was originally assigned to receive envudeucitinib 40 mg BID in OLE, although did not receive treatment.”

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

##### Demographics and prior treatment, ITT population

> “Patient demographics and baseline characteristics were comparable to a general moderate-to-severe psoriasis population (ITT), with the majority of patients being male (70.9%) and white (80.6%); 47.9% were previously treated with biologics and 2.4% with Janus kinase inhibitors (JAKi). The mean age was 49.2 years and the average disease duration was 19.8 years (Table I).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.2-2"></a>

##### Demographic and baseline characteristics by original dose assignment, ITT population

| Characteristic | Original 40 mg QD (N = 82) | Original 40 mg BID (N = 83) | Overall (N = 165) |
| --- | --- | --- | --- |
| Age (y), mean (SD) | “47.5 (12.7)” | “50.8 (12.1)” | “49.2 (12.4)” |
| Male, n (%) | “56 (68.3)” | “61 (73.5)” | “117 (70.9)” |
| Female, n (%) | “26 (31.7)” | “22 (26.5)” | “48 (29.1)” |
| Race: Asian, n (%) | “7 (8.5)” | “4 (4.8)” | “11 (6.7)” |
| Race: Black or African American, n (%) | “5 (6.1)” | “1 (1.2)” | “6 (3.6)” |
| Race: Native Hawaiian or Other Pacific Islander, n (%) | “1 (1.2)” | “2 (2.4)” | “3 (1.8)” |
| Race: White, n (%) | “63 (76.8)” | “70 (84.3)” | “133 (80.6)” |
| Race: Other, n (%) | “6 (7.3)” | “5 (6.0)” | “11 (6.7)” |
| Ethnicity: Hispanic or Latino, n (%) | “26 (31.7)” | “25 (30.1)” | “51 (30.9)” |
| Weight (kg), mean (SD) | “98.1 (28.5)” | “94.0 (23.2)” | “96.0 (26.0)” |
| BMI (kg/m2), mean (SD) | “33.1 (8.8)” | “31.7 (7.4)” | “32.4 (8.1)” |
| Duration of psoriasis (y), mean (SD) | “17.2 (10.9)” | “22.3 (14.3)” | “19.8 (13.0)” |
| Prior treatment with biologics, n (%) | “37 (45.1)” | “42 (50.6)” | “79 (47.9)” |
| Prior treatment with JAKi, n (%) | “1 (1.2)” | “3 (3.6)” | “4 (2.4)” |
| PASI, mean (SD) | “10.2 (7.2)” | “6.8 (7.0)” | “8.5 (7.2)” |
| sPGA score 0, n (%) | “1 (1.2)” | “5 (6.0)” | “6 (3.6)” |
| sPGA score 1, n (%) | “10 (12.2)” | “26 (31.3)” | “36 (21.8)” |
| sPGA score 2, n (%) | “19 (23.2)” | “19 (22.9)” | “38 (23.0)” |
| sPGA score 3, n (%) | “39 (47.6)” | “23 (27.7)” | “62 (37.6)” |
| sPGA score 4, n (%) | “12 (14.6)” | “7 (8.4)” | “19 (11.5)” |
| BSA involvement (%), mean (SD) | “12.9 (13.4)” | “8.7 (11.1)” | “10.8 (12.5)” |
| DLQI, mean (SD) | “5.8 (5.8)” | “4.5 (4.8)” | “5.2 (5.3)” |
| Average pruritus NRS score, mean (SD) | “4.6 (3.0)” | “4.0 (3.1)” | “4.3 (3.1)” |

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Week 52 response rates stated for 40 mg twice daily in the abstract and text, mITT population

> “After 52 weeks of treatment with envudeucitinib 40-mg twice daily, 78% of patients achieved Psoriasis Area and Severity Index (PASI)-75, 61% achieved PASI-90, 39% achieved PASI-100, and 39% achieved sPGA-0.”
> “An increased sPGA response was also observed with 40-mg BID, with 61% of patients reaching sPGA-0/1 at week 52 and 39% reaching sPGA-0 (Fig 1, B, Table III).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.3-2"></a>

##### Week 28 and week 52 skin responses by original and overall 40 mg twice-daily groups, mITT population, mNRI

| Endpoint | Week 28, original 40 mg QD (N = 80) | Week 52, original 40 mg BID (N = 80) | Week 52, overall 40 mg BID (N = 144) |
| --- | --- | --- | --- |
| PASI-75, n (%) | “54 (67.5)” | “62 (77.5)” | “112 (77.8)” |
| PASI-75, 95% CI | “56.1, 77.6” | “66.8, 86.1” | “70.1, 84.3” |
| PASI-90, n (%) | “36 (45.0)” | “49 (61.3)” | “90 (62.5)” |
| PASI-90, 95% CI | “33.8, 56.5” | “49.7, 71.9” | “54.1, 70.4” |
| PASI-100, n (%) | “15 (18.8)” | “31 (38.8)” | “47 (32.6)” |
| PASI-100, 95% CI | “10.9, 29.0” | “28.1, 50.3” | “25.1, 40.9” |
| sPGA-0/1, n (%) | “41 (51.3)” | “49 (61.3)” | “86 (59.7)” |
| sPGA-0/1, 95% CI | “39.8, 62.6” | “49.7, 71.9” | “51.2, 67.8” |
| sPGA-0, n (%) | “15 (18.8)” | “31 (38.8)” | “47 (32.6)” |
| sPGA-0, 95% CI | “10.9, 29.0” | “28.1, 50.3” | “25.1, 40.9” |

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.3-3"></a>

##### Imputation method of the efficacy table

> “All data are based on an mNRI imputation methodology. Non-response was imputed for patients who discontinued due to inadequate response or adverse events, and LOCF if discontinued for all other reasons.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.3-4"></a>

##### Maintenance of STRIDE week 12 PASI-75 response and continued improvement at week 52, 40 mg twice daily

> “Of the PASI-75 responders at week 12 in STRIDE who entered the OLE, 80% of patients in the OLE 40-mg BID arm maintained their PASI-75 response at week 52.”
> “Moreover, of the patients who did not achieve PASI-100 at week 12 in STRIDE, 62% in the OLE 40-mg BID arm showed continued improvement in PASI response at OLE week 52”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.3-5"></a>

##### Improvement in PASI response category from STRIDE week 12 to extension week 52, 40 mg twice daily, mITT population

| Responder status at week 12 of STRIDE | N | Improvement to PASI-75, n (%) | Improvement to PASI-90, n (%) | Improvement to PASI-100, n (%) | Any improvement, n (%) |
| --- | --- | --- | --- | --- | --- |
| Below PASI-75 | “38” | “7 (18.4)” | “8 (21.1)” | “12 (31.6)” | “27 (71.1)” |
| PASI-75 and below PASI-90 | “24” | “----” | “4 (16.7)” | “10 (41.7)” | “14 (58.3)” |
| PASI-90 and below PASI-100 | “11” | “----” | “----” | “4 (36.4)” | “4 (36.4)” |
| Total | “73” | “----” | “----” | “----” | “45 (61.6)” |

Source: [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded)

<a id="topic-3.1.5.8.3-6"></a>

##### Discontinuations among week 52 nonresponders in the original 40 mg twice-daily group

> “Of the 18 non-responders at Week 52, 11 discontinued study early.”

Source: [Blauvelt et al. (2025a)](https://www.alumis.com/file.cfm/18/docs/aad2025_blauvelt_et_al_esk-001_52w_ole_vf.pdf)

<a id="topic-3.1.5.8.3-7"></a>

##### Week 52 compared with extension week 12 in the original 40 mg twice-daily group, mNRI, n = 80

> “These data demonstrated that patients receiving 40 mg twice daily dosing of ESK-001 achieved long-term sustained or increasing clinical responses through Week 52 compared to Week 12 (using modified non-responder imputation, n=80) as measured by PASI 90 (61.3% vs. 52.4%), PASI 100 (38.8% vs. 26.8%), and sPGA 0 (38.8% vs. 32.9%).”

Source: [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)

<a id="topic-3.1.5.8.3-8"></a>

##### Week 28 PASI and sPGA responses with 40 mg twice daily, mNRI, March 2024 data cut

> “PASI-75, PASI-90, and PASI-100 responses (mNRI) with 40 mg BID at Week 28 of 83%, 63%, and 31%, respectively”
> “sPGA 0/1 and 0 responses (mNRI) with 40 mg BID at Week 28 of 68% and 35%, respectively”
> “Data as of March 1, 2024”

Source: [Blauvelt et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv_late_breaker_presentation_final.pdf)

<a id="topic-3.1.5.8.3-9"></a>

##### Treat-to-target thresholds at week 52 with 40 mg twice daily, post-hoc analysis

> “At Week 52, 60% of patients on envudeucitinib 40 mg BID achieved BSA ≤1%”
> “Nearly 90% PASI improvement from baseline at 52 weeks with envudeucitinib 40 mg BID”

Source: [Armstrong et al. (2025c)](https://www.alumis.com/file.cfm/613/docs/2025_fall_clinical_dermatology_conference.pdf)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

##### DLQI and pruritus responses at week 52 stated in the text, 40 mg twice daily

> “Improvements in signs and symptoms were accompanied by dose-dependent improvements in QoL, as measured by DLQI and pruritus NRS (Table III). In the 40-mg BID arm at week 52, 61% of patients achieved DLQI-0/1 and approximately 80% of patients achieved itch symptom control at week 52 (NRS <4). Post-hoc analysis showed that 62% of patients in the 40-mg BID overall group achieved ≥4 point improvement from baseline in worst pruritus NRS score at week 52, with onset of improvement shown as early as week 4.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.4-2"></a>

##### Week 28 and week 52 patient-reported outcomes by original and overall 40 mg twice-daily groups, mITT population, mNRI

| Endpoint | Week 28, original 40 mg QD (N = 80) | Week 52, original 40 mg BID (N = 80) | Week 52, overall 40 mg BID (N = 144) |
| --- | --- | --- | --- |
| DLQI 0/1, n (%) | “41 (51.3)” | “49 (61.3)” | “87 (60.4)” |
| DLQI 0/1, 95% CI | “39.8, 62.6” | “49.7, 71.9” | “51.9, 68.5” |
| DLQI 4-point decrease, n (%) | “49 (61.3)” | “55 (68.8)” | “103 (71.5)” |
| DLQI 4-point decrease, 95% CI | “49.7, 71.9” | “57.4, 78.7” | “63.4, 78.7” |
| Average pruritus NRS score below 4, n (%) | “54 (67.5)” | “65 (81.3)” | “115 (79.9)” |
| Average pruritus NRS score below 4, 95% CI | “56.1, 77.6” | “71.0, 89.1” | “72.4, 86.1” |
| Worst pruritus NRS score below 4, n (%) | “51 (63.8)” | “63 (78.8)” | “112 (77.8)” |
| Worst pruritus NRS score below 4, 95% CI | “52.2, 74.2” | “68.2, 87.1” | “70.1, 84.3” |
| Improvement in worst pruritus NRS score of at least 4, post-hoc, n (%) | “44 (55.0)” | “47 (58.8)” | “89 (61.8)” |
| Improvement in worst pruritus NRS score of at least 4, post-hoc, 95% CI | “43.5, 66.2” | “47.2, 69.6” | “53.3, 69.8” |

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.4-3"></a>

##### Itch control and DLQI at week 52 stated in the company release, original 40 mg twice-daily group

> “At Week 52, patients maintained robust clinical improvements in control of itch (NRS≤4, 81.3%) and quality-of-life (DLQI0/1, 61.3%).”

Source: [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)

<a id="topic-3.1.5.8.4-4"></a>

##### Minimal or no impact on quality of life at weeks 12 and 52 with 40 mg twice daily

> “At Week 12 and 52, >60% of patients on envudeucitinib 40 mg BID reported minimal or no impact on QoL”

Source: [Armstrong et al. (2025c)](https://www.alumis.com/file.cfm/613/docs/2025_fall_clinical_dermatology_conference.pdf)

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Adverse events with exposure-adjusted incidence rates through week 52, safety analysis population

| Event, n (%) [EAIR] | Original 40 mg QD (N = 82) | Overall 40 mg BID (N = 147) | Overall (N = 164) |
| --- | --- | --- | --- |
| Patients with at least 1 TEAE | “50 (61.0) [122.76]” | “73 (49.7) [102.33]” | “108 (65.9) [108.18]” |
| Patients with TEAE leading to study drug discontinuation | “1 (1.2) [1.55]” | “5 (3.4) [4.19]” | “6 (3.7) [3.26]” |
| Patients with TEAE grade 3 or higher | “3 (3.7) [4.66]” | “6 (4.1) [5.12]” | “8 (4.9) [4.42]” |
| Upper respiratory tract infection | “3 (3.7) [4.71]” | “13 (8.8) [11.66]” | “16 (9.8) [9.20]” |
| Nasopharyngitis | “10 (12.2) [16.88]” | “6 (4.1) [5.15]” | “14 (8.5) [8.09]” |
| COVID-19 | “3 (3.7) [4.74]” | “8 (5.4) [6.88]” | “11 (6.7) [6.17]” |
| Headache | “5 (6.1) [8.28]” | “5 (3.4) [4.28]” | “10 (6.1) [5.71]” |
| Patients with at least 1 treatment-emergent SAE | “2 (2.4) [3.10]” | “4 (2.7) [3.39]” | “6 (3.7) [3.29]” |
| Patients with SAEs related to study drug | “2 (2.4) [3.10]” | “2 (1.4) [1.67]” | “4 (2.4) [2.17]” |
| Patients with TEAE leading to death | “0 (0) [-]” | “0 (0) [-]” | “0 (0) [-]” |

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-2"></a>

##### Adverse events leading to discontinuation, frequency threshold, and severity of the most frequent events

> “TEAEs leading to drug discontinuation in 6 patients included dyspepsia, hypersensitivity, osteomyelitis, pruritus, renal cell carcinoma (envudeucitinib 40-mg BID), and non-small cell lung cancer (envudeucitinib 40-mg QD).”
> “TEAEs reported by 5% or more patients in any treatment group.”
> “All events of upper respiratory tract infection, nasopharyngitis, COVID-19, and headache were grade 1 (mild) or grade 2 (moderate) in severity.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-3"></a>

##### Overall tolerability, severity, acne, and folliculitis

> “Treatment with envudeucitinib over 52 weeks in the OLE was generally safe and well-tolerated with no deaths and a low rate of study drug discontinuation due to AEs (3.7%) (Table II). The overall number of patients with at least 1 TEAE was 65.9%, with the majority of TEAEs being mild or moderate in severity (23.8% and 37.2%, respectively).”
> “Rates of acne and folliculitis were low at 3.0% and 2.4%, respectively, all being mild or moderate in severity and self-limited.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-4"></a>

##### Comparison of the once-daily and twice-daily arms, including related adverse events

> “Comparison of the 40-mg QD arm and the 40-mg BID arm showed no dose-dependent effects on the overall frequency of AEs, nor on the numbers of most frequent TEAEs.”
> “TEAEs considered related to the study drug occurred in 14.6% of patients in the 40-mg QD arm compared to 10.2% in the 40-mg BID arm, while SAEs related to the study drug occurred in 2 patients in each group (2.4% and 1.4%, respectively).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-5"></a>

##### Treatment-related adverse events with exposure-adjusted incidence rates, September 2024 data cut

> “Subjects with TEAE related to study drug 12 (15) 20.19 15 (10) 13.83 26 (16) 15.70”
> “Safety data displayed are based on 06 SEP 2024 data cut of ongoing OLE study.”

Source: [Blauvelt et al. (2025a)](https://www.alumis.com/file.cfm/18/docs/aad2025_blauvelt_et_al_esk-001_52w_ole_vf.pdf)

<a id="topic-3.1.5.8.5-6"></a>

##### Serious adverse events: four considered related and two considered unrelated

> “The overall frequency of patients with at least 1 SAE was 3.7% (n = 6) (Table II). Four SAEs reported in 4 patients were considered related to study drug by the investigator: peritonsillar abscess (40-mg BID), non-small cell lung cancer in a patient with a strong family history (3 first-degree relatives) and genetic subtype consistent with familial lung cancer (40-mg QD), clear-cell type renal cell carcinoma incidentally identified during the course of evaluation for urolithiasis (40-mg BID), and arthritis in a patient with history of prior inflammatory arthritic event (40-mg QD). Separately, 1 patient with multiple co-morbidities, including diabetes, long-standing foot ulcer, and recurrent episodes of lower limb cellulitis, had SAEs of sepsis, septic shock, and cellulitis (40-mg BID), and 1 patient with positive medical history had a SAE of asthma exacerbation, all considered unrelated to study drug (after switch from 40-mg QD to 40-mg BID).”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-7"></a>

##### Laboratory values, lipids, cytopenia, rhabdomyolysis, and tuberculosis

> “Laboratory assessments did not show any clinically significant abnormalities, including no episodes of acute liver or renal dysfunction, nor identified any liver, renal, or hematological trends of concern. Throughout 52 weeks of envudeucitinib treatment, mean lab values remained stable and within normal limits across both dose arms”
> “Consistent with the co-morbidities associated with psoriasis and high BMI of the study population, the day 1 lipid panel values were at the upper limit of normal and remained stable throughout the 52 weeks”
> “There were no AEs of cytopenia or rhabdomyolysis, and no cases of tuberculosis.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-3.1.5.8.5-8"></a>

##### Herpes zoster, electrocardiograms, and thromboembolic events

> “There were 2 cases of herpes zoster, neither of which resulted in envudeucitinib treatment interruption or study discontinuation, and both cases completely resolved (1 with and 1 without antiviral treatment).”
> “There were neither significant changes in ECG findings during 52 weeks of envudeucitinib treatment, nor were thromboembolic events reported.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary

- The authors state that this was an open-label study with limited sample size and no placebo or active comparator.
- No formal power calculation was performed; the sample consisted of STRIDE completers who qualified and chose to enroll. The extension was not initiated in the Czech Republic, which made 25 STRIDE completers ineligible, and the study was conducted at North American sites only.
- Dose assignment followed the STRIDE arm for participants from the 10 mg QD and 20 mg QD arms (40 mg QD) and the 20 mg BID and 40 mg BID arms (40 mg BID); participants from the placebo and 40 mg QD arms were allocated to either dose. The ClinicalTrials.gov record lists the allocation as randomized.
- A protocol amendment on 2 January 2024 moved all participants to 40 mg BID between weeks 40 and 64, so the overall 40 mg BID group (N = 148, intent-to-treat) includes 65 participants who switched from 40 mg QD.
- Efficacy baseline was STRIDE Day 1, and participants entered the extension with a mean PASI of 8.5. Responder analyses used modified nonresponder imputation, carrying the last observation forward for discontinuations other than for AEs or inadequate response.
- Week 52 PASI 100 with 40 mg BID is 39% in the article text, 31 of 80 (38.8%) in the original 40 mg BID group, and 47 of 144 (32.6%) in the overall 40 mg BID group. Itch control in the original 40 mg BID group is reported as “NRS≤4, 81.3%” in a press release and as average pruritus NRS below 4 in 65 participants (81.3%) in the article table.
- Data cutoffs differ: the supplement includes data from 18 November 2024, and a congress poster by Blauvelt et al. displays safety data from the 06 SEP 2024 data cut. The treat-to-target analyses and the analysis of an improvement of at least 4 points in worst pruritus NRS are post hoc.
- The study is ongoing; 126 participants (76.4%) were continuing treatment at the 52-week data cut-off, and study completion is estimated for 2027-12-31.

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext); [Papp et al. (2025c)](https://data.mendeley.com/public-files/datasets/vwzkp28fwb/files/476869b0-5f17-43ff-8b49-1650630bf460/file_downloaded); [ClinicalTrials.gov NCT05739435](https://clinicaltrials.gov/study/NCT05739435); [Blauvelt et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv_late_breaker_presentation_final.pdf); [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm); [Blauvelt et al. (2025a)](https://www.alumis.com/file.cfm/18/docs/aad2025_blauvelt_et_al_esk-001_52w_ole_vf.pdf); [Armstrong et al. (2025c)](https://www.alumis.com/file.cfm/613/docs/2025_fall_clinical_dermatology_conference.pdf)

<a id="topic-3.1.5.9-2"></a>

#### Open-label design, sample size, and absence of a control group as stated by the authors

> “This was an open-label study with limited sample size and no control.”
> “However, important limitations of this open-label study should be acknowledged, including the lack of placebo or active comparator and the relatively small sample size.”

Source: [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

Additional sources: [Noot et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41161603/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
